会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明申请
    • VACCINE FORMULATION FOR PROPHYLAXIS AND TREATMENT OF CHANDIPURA VIRUS INFECTIONS IN MAMMALS
    • 野生动物疫苗制剂和治疗肉鸡病原菌感染
    • WO2012073257A2
    • 2012-06-07
    • PCT/IN2011/000817
    • 2011-11-29
    • BHARAT BIOTECH INTERNATIONAL LIMITEDELLA, Krishna MurthySUMATHY, K.
    • ELLA, Krishna MurthySUMATHY, K.
    • A61K39/205A61K39/12A61K2039/5252A61K2039/55505A61K2039/55583C12N2760/20034Y02A50/39
    • The present invention is related to pharmaceutical formulations capable of eliciting protective immune response against Chandipura virus infection in humans and other mammalian hosts. The immunogenic formulation comprises Chandipura virus glycoprotein (G protein) and/or nucleoprotein expressed as recombinant proteins and purified from host cells. Vaccine compositions comprising the recombinant proteins elicit neutralizing antibodies similar to the vaccine compositions of purified inactivated Chandipura virus in a stable formulation. Methods of inactivating Chandipura virus for use as a candidate vaccine are disclosed. The vaccine compositions have been formulated with adjuvants to potentiate the immune response. The vaccine compositions disclosed in the invention are highly immunogenic and elicit protective immune response in mammalian host. The immunogenic compositions are formulated for in vivo administration to humans. The immunogenic preparation will also find use in diagnosing for the presence of the virus
    • 本发明涉及能够在人类和其他哺乳动物宿主中引发对钱氏杜氏病毒感染的保护性免疫应答的药物制剂。 免疫原性制剂包含由重组蛋白质表达并从宿主细胞纯化的Chandipura病毒糖蛋白(G蛋白)和/或核蛋白。 包含重组蛋白的疫苗组合物引起与稳定制剂中纯化的灭活的Chandipura病毒的疫苗组合物类似的中和抗体。 公开了将Chandipura病毒灭活用作候选疫苗的方法。 疫苗组合物已经用佐剂配制以增强免疫应答。 本发明公开的疫苗组合物是高度免疫原性的并且在哺乳动物宿主中引发保护性免疫应答。 配制免疫原性组合物用于体内给予人。 免疫原性制剂也可用于诊断病毒的存在
    • 3. 发明申请
    • VACCINE FORMULATION FOR PROPHYLAXIS AND TREATMENT OF CHANDIPURA VIRUS INFECTIONS IN MAMMALS
    • 用于预防和治疗哺乳动物CHANDIPURA病毒感染的疫苗制剂
    • WO2012073257A3
    • 2012-10-11
    • PCT/IN2011000817
    • 2011-11-29
    • BHARAT BIOTECH INT LTDELLA KRISHNA MURTHYSUMATHY K
    • ELLA KRISHNA MURTHYSUMATHY K
    • A61K39/12A61K39/205
    • A61K39/205A61K39/12A61K2039/5252A61K2039/55505A61K2039/55583C12N2760/20034
    • The present invention is related to pharmaceutical formulations capable of eliciting protective immune response against Chandipura virus infection in humans and other mammalian hosts. The immunogenic formulation comprises Chandipura virus glycoprotein (G protein) and/or nucleoprotein expressed as recombinant proteins and purified from host cells. Vaccine compositions comprising the recombinant proteins elicit neutralizing antibodies similar to the vaccine compositions of purified inactivated Chandipura virus in a stable formulation. Methods of inactivating Chandipura virus for use as a candidate vaccine are disclosed. The vaccine compositions have been formulated with adjuvants to potentiate the immune response. The vaccine compositions disclosed in the invention are highly immunogenic and elicit protective immune response in mammalian host. The immunogenic compositions are formulated for in vivo administration to humans. The immunogenic preparation will also find use in diagnosing for the presence of the virus
    • 本发明涉及能够在人和其他哺乳动物宿主中引发针对金迪普拉病毒感染的保护性免疫应答的药物制剂。 免疫原性制剂包含表达为重组蛋白并从宿主细胞纯化的金迪普拉病毒糖蛋白(G蛋白)和/或核蛋白。 包含重组蛋白的疫苗组合物在稳定制剂中引发与纯化的灭活金迪普拉病毒的疫苗组合物相似的中和抗体。 公开了灭活金迪普拉病毒以用作候选疫苗的方法。 已经用佐剂配制疫苗组合物以增强免疫应答。 本发明公开的疫苗组合物具有高度免疫原性并在哺乳动物宿主中引起保护性免疫应答。 配制免疫原性组合物用于体内施用给人。 免疫原性制剂也可用于诊断病毒的存在